Endonovo Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENDV research report →
Companywww.endonovo.com
Endonovo Therapeutics, Inc. , a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema.
- CEO
- Alan Brian Collier
- IPO
- 2012
- Employees
- 1
- HQ
- Woodland Hills, CA, US
Price Chart
Valuation
- Market Cap
- $31.88K
- P/E
- -0.06
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -9.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 6.45%
- ROIC
- 4.03%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-2,176,130 · 22.21%
- EPS
- $-0.00 · 60.78%
- Op Income
- $-945,766
- FCF YoY
- -142.78%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -8.45
- Avg Volume
- 792.86K
Get TickerSpark's AI analysis on ENDV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 20 | Collier Alan Brian | buy | 100 |
| Jul 1, 20 | Collier Alan Brian | buy | 100 |
| Jun 30, 20 | Collier Alan Brian | buy | 200 |
| Feb 22, 20 | Collier Alan Brian | buy | 100 |
| Jan 2, 20 | Collier Alan Brian | buy | 100 |
| Dec 30, 19 | Collier Alan Brian | buy | 100 |
| Dec 16, 19 | Collier Alan Brian | buy | 500 |
| Dec 12, 19 | Collier Alan Brian | buy | 1,000 |
| Dec 11, 19 | Collier Alan Brian | buy | 100 |
| Dec 11, 19 | Collier Alan Brian | buy | 1,000 |
Our ENDV Coverage
We haven't published any research on ENDV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENDV Report →